Trial Profile

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2025 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025
24 Oct 2025 According to a Xencor media release, the company is on-track with first dose-expansion cohort now selected and are enrolling patients as company continue to dose escalate. the company will be able to select a recommended Phase 3 dose during 2026 to support the initiation of our first pivotal study in advanced ccRCC during 2027. Xencor will host a webcast today at 1:30 a.m. ET (10:30 a.m. PT) to discuss the initial results from this trial.
24 Oct 2025 According to a Xencor media release, results from this trial were presented in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com